SENS vs. MLAB, PRLD, MACK, GTHX, FHTX, ARAY, ACRV, PSTX, IMMP, and DSGN
Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include Mesa Laboratories (MLAB), Prelude Therapeutics (PRLD), Merrimack Pharmaceuticals (MACK), G1 Therapeutics (GTHX), Foghorn Therapeutics (FHTX), Accuray (ARAY), Acrivon Therapeutics (ACRV), Poseida Therapeutics (PSTX), Immutep (IMMP), and Design Therapeutics (DSGN). These companies are all part of the "medical" sector.
Senseonics (NYSE:SENS) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.
Mesa Laboratories received 216 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 63.82% of users gave Mesa Laboratories an outperform vote while only 25.00% of users gave Senseonics an outperform vote.
In the previous week, Senseonics and Senseonics both had 2 articles in the media. Mesa Laboratories' average media sentiment score of 1.46 beat Senseonics' score of 0.00 indicating that Mesa Laboratories is being referred to more favorably in the news media.
Senseonics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Mesa Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
12.4% of Senseonics shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 3.9% of Senseonics shares are owned by company insiders. Comparatively, 5.2% of Mesa Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Senseonics currently has a consensus price target of $1.25, indicating a potential upside of 200.70%. Mesa Laboratories has a consensus price target of $130.00, indicating a potential upside of 25.98%. Given Senseonics' higher possible upside, equities research analysts clearly believe Senseonics is more favorable than Mesa Laboratories.
Mesa Laboratories has a net margin of 0.45% compared to Senseonics' net margin of -270.13%. Mesa Laboratories' return on equity of 7.41% beat Senseonics' return on equity.
Mesa Laboratories has higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
Mesa Laboratories beats Senseonics on 13 of the 16 factors compared between the two stocks.
Get Senseonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senseonics Competitors List
Related Companies and Tools
